Foskett Amanda, Alnaeeli Mawadda, Wang Li, Teng Ruifeng, Noguchi Constance T
Molecular Medicine Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
J Biomed Biotechnol. 2011;2011:373781. doi: 10.1155/2011/373781. Epub 2011 Apr 20.
Erythropoietin (Epo) is a pleotropic cytokine with several nonhematopoietic tissue effects. High-dose Epo treatment-mediated effects on body weight, fat mass and glucose tolerance have recently been reported, thus extending its pleotropic effects to fat and glucose metabolism. However, the exact dose range of Epo treatment required for such effects remains unidentified to date. We investigated Epo dosage effect (up to 1000 U/kg) on hematocrit, body weight, body composition, glucose metabolism, food intake, and physical activity, during high-fat diet-induced obesity. We report that Epo doses (1000, 600, 300, and 150 U/kg) significantly reduced body weight gain and fat mass, while, only Epo doses of 300 U/kg and higher significantly affected glucose tolerance. None of the tested Epo doses showed any detectable effects on food intake, and only 1000 U/kg dose significantly increased physical activity, suggesting that these parameters may only be partially responsible for the metabolic effects of Epo treatment.
促红细胞生成素（Epo）是一种具有多种非造血组织效应的多效性细胞因子。最近有报道称，高剂量促红细胞生成素治疗对体重、脂肪量和糖耐量有影响，从而将其多效性作用扩展到脂肪和葡萄糖代谢。然而，迄今为止，产生这些效应所需的促红细胞生成素治疗的确切剂量范围仍未明确。我们研究了在高脂饮食诱导的肥胖过程中，促红细胞生成素剂量效应（高达1000 U/kg）对血细胞比容、体重、身体成分、葡萄糖代谢、食物摄入量和身体活动的影响。我们报告称，促红细胞生成素剂量（1000、600、300和150 U/kg）显著降低了体重增加和脂肪量，而只有300 U/kg及以上的促红细胞生成素剂量对糖耐量有显著影响。所测试的促红细胞生成素剂量均未显示出对食物摄入量有任何可检测到的影响，只有1000 U/kg剂量显著增加了身体活动，这表明这些参数可能只是促红细胞生成素治疗代谢效应的部分原因。
